Can a patent ductus arteriosus (PDA) cause pulmonary hypertension in patients of any age?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Patent Ductus Arteriosus Cause Pulmonary Hypertension?

Yes, patent ductus arteriosus (PDA) absolutely causes pulmonary hypertension, and this is one of its most serious complications that can progress to irreversible pulmonary vascular disease and Eisenmenger syndrome if left untreated. 1

Mechanism and Pathophysiology

The left-to-right shunt through a PDA directly exposes the pulmonary vasculature to increased blood flow and pressure, leading to elevated pulmonary artery pressures. 1 The severity depends on PDA size and duration:

  • Moderate to large PDAs result in elevated pulmonary pressures from the outset 1
  • In patients reaching adulthood with moderate PDA, either left ventricular volume overload or pulmonary arterial hypertension may predominate, with genetic predisposition playing a role 1
  • Adult patients with large PDAs typically develop Eisenmenger physiology with reversal of shunt direction (right-to-left) 1

Clinical Evidence of the PDA-Pulmonary Hypertension Link

The relationship is well-documented across multiple studies:

  • 96% of surgical PDA patients had pulmonary hypertension in one surgical series 2
  • A direct correlation exists between ductus diameter and pulmonary artery pressure—as ductus diameter increases, pulmonary artery pressure increases significantly 2
  • Patients with PDA and severe pulmonary hypertension can have near-systemic or systemic right ventricular pressures 3, 4

Clinical Presentations Based on Severity

Small PDA

  • Normal pulmonary artery pressure 1, 5
  • No left ventricular volume overload 5
  • Continuous machinery murmur present 1

Moderate PDA

  • Two distinct phenotypes:
    • Predominant LV volume overload with dilated left ventricle (may present with left heart failure) 1
    • Predominant pulmonary arterial hypertension with pressure-overloaded right ventricle (may present with right heart failure) 1

Large PDA

  • Eisenmenger physiology with differential cyanosis and clubbing 1
  • Lower extremities cyanotic (sometimes left arm too) because unoxygenated blood from the ductus enters the aorta distal to the left subclavian artery 1
  • Only systolic murmur may be heard (continuous murmur disappears) 1

Critical Diagnostic Pitfall

Do not miss differential cyanosis—always check oxygen saturation in all four extremities to detect right-to-left shunting at the ductal level. 1, 5 Upper extremities may have normal saturation while lower extremities are cyanotic and clubbed. 1

Implications for Management

When Closure is Indicated

PDA should be closed when pulmonary hypertension is present BUT pulmonary artery pressure remains less than 2/3 of systemic pressure or pulmonary vascular resistance is less than 2/3 of systemic vascular resistance. 1, 5

When Closure is Contraindicated

PDA closure is absolutely contraindicated in patients with established Eisenmenger physiology (net right-to-left shunt), as closure would be harmful. 1, 6 In cases of doubt, pulmonary vascular resistance testing is mandatory. 1

Staged Approach for Severe Pulmonary Hypertension

For patients with severe but potentially reversible pulmonary hypertension:

  • Aggressive medical treatment of pulmonary hypertension first creates a window of opportunity for safe PDA closure 3
  • Balloon test occlusion during cardiac catheterization is critical to determine safety of closure 3
  • Successful closure requires mean pulmonary arterial pressures to decrease markedly after trial occlusion (e.g., from 78 mmHg to 41 mmHg) and systemic oxygen saturation to remain >90% 4
  • If pulmonary arterial pressure increases by >10 mmHg after trial occlusion or oxygen saturation drops significantly, closure should not proceed 4

Reversibility After Closure

When PDA is closed before irreversible pulmonary vascular disease develops, pulmonary artery pressures decrease significantly postoperatively. 2 However:

  • The decrease is faster in isolated PDA compared to PDA with congenital heart disease and right-left shunt 2
  • Follow-up shows pulmonary artery pressure normalizes or reaches upper normal limits in most successfully closed cases 7
  • Left untreated, the large PDA inevitably results in irreversible pulmonary vascular disease 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Hemodynamically and Clinically Stable Patent Ductus Arteriosus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Patent Ductus Arteriosus in Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Closure of a large patent ductus arteriosus in children and adults with pulmonary hypertension.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, 2010

Related Questions

Can patent ductus arteriosus (PDA) occur in adults?
What is the most common cause of deterioration in a patient with patent ductus arteriosus (PDA) presenting with cyanosis, irregular heart rhythm, and S3 gallop?
What is the most common cause of deterioration in a patient with a patent ductus arteriosus (PDA), presenting with cyanosis, irregular heart rhythm, and an S3 gallop?
What is the most common cause of deterioration in a patient with patent ductus arteriosus (PDA) presenting with cyanosis, irregular heart rhythm, and an S3 gallop?
What is the most common cause of deterioration in a patient with a patent ductus arteriosus (PDA) presenting with cyanosis, irregular heart rhythm, and an S3 gallop?
How long should Eliquis (apixaban) be held in an adult patient with atrial fibrillation or venous thromboembolism before a bone marrow biopsy?
What is the recommended signature (sig) for ondansetron (Zofran) for an elderly female patient with post-operative nausea and difficulty swallowing?
What are the risks and recommendations for long-term use of oxymetazoline (decongestant) in patients, particularly those with a history of hypertension?
What is the appropriate dose and timing of dexamethasone (corticosteroid) as a preoperative medication for an adult patient with liver cancer undergoing Transarterial Chemoembolization (TACE)?
What are the treatment options for an intraosseous (within the bone) hemangioma?
What is the best course of action for a patient with persistent cough, shortness of breath, and bilateral (b/l) wheezing, who has been using an albuterol (albuterol) inhaler and Advair (fluticasone-salmeterol), despite an oxygen saturation of 97%, and a history of upper respiratory tract infection symptoms that started one week ago?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.